Ciraparantag not checked

Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc. · PER977 · AMAG 977

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
3 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Main trialPhase 2
“This study is a randomized, single-blind, placebo-controlled study to assess the efficacy and safety of ciraparantag administered to healthy volunteers anticoagulated with apixaban measuring clotting times using Whole Blood Clotting Time (WBCT).”In the company’s words, NCT03288454 on ClinicalTrials.gov
Other names
PER977 · AMAG 977

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 2Completed 5 Aug 2019 Phase 2 Study of Apixaban Reversal by Ciraparantag as Measured by WBCT
Phase 2Completed 12 Nov 2019 Phase 2 Study of Rivaroxaban Reversal by Ciraparantag as Measured by WBCT
Phase 2Terminated 26 Aug 2023 Study of Ciraparantag for Reversal of Anticoagulation Induced by Edoxaban, Apixaban or Rivaroxaban in Healthy Adults
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Ciraparantag

Following is part of Solo: you see every change to Ciraparantag the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in